| Literature DB >> 26582734 |
Thibault Brotelle1, Jacques-Olivier Bay2.
Abstract
Among many cancer cells signaling pathways, PI3K-AKT-mTOR plays a major role in growth, proliferation and cellular survival. This is a complex pathway activated either by an extracellular way (receptors with tyrosine kinase activity) or by an intracellular way with transformed or overexpressed proteins involved in the signal transduction. To date, there are many applications of mTOR inhibitors in oncology with an expanding development rapidly. However, resistances appear to mTOR inhibitors which lead to 2nd generation mTOR inhibitors development. A better knowledge of predictive and prognostic biomarkers will allow to specify the group of patients who may benefit from these treatments and help to the choice.Entities:
Keywords: Biomarker; Everolimus; Inhibiteur mTOR; Marqueur biologique; PI3K-AKT-mTOR; Resistance; Résistance; Temsirolimus; mTOR inhibitor; Évérolimus
Mesh:
Substances:
Year: 2015 PMID: 26582734 DOI: 10.1016/j.bulcan.2015.09.011
Source DB: PubMed Journal: Bull Cancer ISSN: 0007-4551 Impact factor: 1.276